Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Kyowa Hakko Kirin Nabs ProStrakan

by Lisa M. Jarvis
February 28, 2011 | A version of this story appeared in Volume 89, Issue 9

Kyowa Hakko Kirin has agreed to pay roughly $470 million for Scottish specialty pharmaceutical firm ProStrakan Group. Tokyo-based KHK says the deal was driven by the potential to quickly expand in the U.S. and Europe. ProStrakan brings clinical and regulatory experience, along with a sales force that will enable KHK to launch its own pipeline of products in those markets. Several suitors have approached Pro­Strakan in recent months, but KHK was the best fit in terms of complementary product portfolios and geographic presence, Pro­Strakan’s chairman, Peter Allen, says.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.